- Home
- SGC vs NKTR Comparison
SGC vs NKTR Comparison
Compare SGC & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- NKTR
- Stock Information
- Founded
- SGC 1920
- NKTR 1990
- Country
- SGC United States
- NKTR United States
- Employees
- SGC N/A
- NKTR N/A
- Industry
- SGC Apparel
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- NKTR Health Care
- Exchange
- SGC Nasdaq
- NKTR Nasdaq
- Market Cap
- SGC 252.6M
- NKTR 238.7M
- IPO Year
- SGC N/A
- NKTR 1994
- Fundamental
- Price
- SGC $15.02
- NKTR $1.29
- Analyst Decision
- SGC Strong Buy
- NKTR Buy
- Analyst Count
- SGC 2
- NKTR 4
- Target Price
- SGC $22.00
- NKTR $2.50
- AVG Volume (30 Days)
- SGC 78.3K
- NKTR 1.0M
- Earning Date
- SGC 11-04-2024
- NKTR 11-05-2024
- Dividend Yield
- SGC 3.74%
- NKTR N/A
- EPS Growth
- SGC N/A
- NKTR N/A
- EPS
- SGC 0.68
- NKTR N/A
- Revenue
- SGC $553,945,000.00
- NKTR $93,157,000.00
- Revenue This Year
- SGC $4.89
- NKTR N/A
- Revenue Next Year
- SGC $4.84
- NKTR N/A
- P/E Ratio
- SGC $22.21
- NKTR N/A
- Revenue Growth
- SGC 1.22
- NKTR 6.17
- 52 Week Low
- SGC $7.40
- NKTR $0.41
- 52 Week High
- SGC $21.80
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- SGC 50.20
- NKTR 52.81
- Support Level
- SGC $14.95
- NKTR $1.26
- Resistance Level
- SGC $15.28
- NKTR $1.42
- Average True Range (ATR)
- SGC 0.34
- NKTR 0.09
- MACD
- SGC 0.01
- NKTR 0.01
- Stochastic Oscillator
- SGC 40.00
- NKTR 58.06
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.